Glioblastoma multiforme (GBM) is a WHO grade IV glioma and the most common malignant,
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …

Simple Summary Patients with glioblastoma—the most frequent and malignant primary brain
tumor—have a poor prognosis with a median survival of less than 15 months. Despite …

Radiation therapy is a mainstay of cancer treatment but does not always lead to complete
tumor regression. Here we combine radiotherapy with blockade of the 'don't-eat-me'cell …

The development of gene therapies for the treatment of diseases of the central nervous
system has been hindered by the limited availability of adeno-associated viruses (AAVs) that …

High-grade glioma is one of the deadliest primary tumors of the central nervous system.
Despite the many novel immunotherapies currently in development, it has been difficult to …

Brain cancers carry bleak prognoses, with therapeutic advances helping only a minority of
patients over the past decade. The brain tumour microenvironment (TME) is highly …

Background Glioblastoma (GBM) is refractory to immune checkpoint inhibitor (ICI) therapy.
We sought to determine to what extent this immune evasion is due to intrinsic properties of …

Background Though currently approved immunotherapies, including chimeric antigen
receptor T cells and checkpoint blockade antibodies, have been successfully used to treat …

Introduction The increasingly detailed genetic characterization of glioblastoma (GBM) has
failed to translate into meaningful breakthroughs in treatment. This is likely to be attributed to …

Simple Summary Combination of radiotherapy and immunotherapy to antagonize tumors is
one of hotspot issues currently. Immunotherapy can effectively alleviate the non-lasting …